Investigational drug · Phase 3
Staccato alprazolam
Also called: UCB7538
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stereotypical Prolonged Seizures.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "Staccato alprazolam"
First trial start
2021
Dec 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Staccato alprazolam", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stereotypical Prolonged Seizures
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Staccato alprazolam" as an intervention, largest first.
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPivotal-lookingRecruiting
NCT05077904 · 350 participants (planned) · Start Dec 7, 2021 · Primary completion Mar 29, 2027
Drug: Staccato alprazolam · For: Stereotypical Prolonged Seizures
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 183 sites in all
- A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPivotal-lookingEnrolling by invitation
NCT05076617 · 300 participants (planned) · Start Feb 3, 2022 · Primary completion Nov 30, 2028
Drug: Staccato alprazolam · For: Stereotypical Prolonged Seizures
Sites: Phoenix, Arizona; Scottsdale, Arizona; Downey, California · 133 sites in all
- Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure PatternPivotal-lookingCompleted
Engage Therapeutics, Inc.Industry
NCT03478982 · 156 participants · Start Mar 16, 2018 · Primary completion Dec 22, 2019
Drug: Staccato Alprazolam; Placebos · For: Epilepsy
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 67 sites in all
NCT04802746 · 78 participants · Start Mar 9, 2021 · Primary completion Nov 22, 2021
Drug: Alprazolam · For: Healthy Study Participants; Participants With Mild Asthma
Sites: North Dartmouth, Massachusetts; Raleigh, North Carolina
NCT07020988 · 55 participants · Start Jun 12, 2025 · Primary completion Jan 6, 2026
Drug: Staccato Alprazolam; Midazolam and 1 more · For: Healthy Participants
Sites: Glendale, California
- Staccato Alprazolam Single Dose PKCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00444522 · 50 participants · Start Jun 2005 · Primary completion Aug 2005
Drug: Alprazolam thermal aerosol · For: Healthy
- Staccato Alprazolam in Panic AttackCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00477451 · 49 participants · Start May 2007 · Primary completion Apr 2008
Drug: Inhaled placebo; Inhaled alprazolam 1 mg and 2 more · For: Treatment of Induced Panic Attack
Sites: Brooklyn, New York; New York, New York · 3 sites in all
- Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-SmokersCompleted
Engage Therapeutics, Inc.Industry
NCT03516305 · 36 participants · Start Apr 6, 2018 · Primary completion Aug 1, 2018
Drug: Staccato Alprazolam 1 mg · For: Healthy
Sites: Eatontown, New Jersey
- Staccato Alprazolam Abuse LiabilityCompleted
Nova Pneuma Inc.Industry
NCT00603980 · 31 participants · Start Jan 2008 · Primary completion Jan 2009
Drug: Inhaled placebo + oral placebo; Inhaled alprazolam 0.5 mg and 7 more · For: Abuse Liability of Staccato Alprazolam
Sites: Baltimore, Maryland
NCT04782388 · 30 participants · Start Mar 4, 2021 · Primary completion Apr 26, 2021
Drug: Alprazolam · For: Healthy Study Participants
Sites: Anaheim, California
Newest research
PubMed records naming it or its code names, newest first.
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial.
Miller SD, LaForce CF, Barlow L, et al. · Pulm Pharmacol Ther 2026
- Novel pharmacological therapies in development.
Perucca P, Perucca E · Curr Opin Neurol 2026
- Pharmacokinetics and tolerability of single-dose Staccato® alprazolam in adolescents with epilepsy, and population pharmacokinetic analysis to support dose selection in adolescents.
Klein P, Aungaroon G, Biton V, et al. · Epilepsia 2026
- Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders.
Detyniecki K, Strzelczyk A, Roebling R, et al. · CNS Drugs 2025
- Pharmacokinetics of Staccato® alprazolam in healthy adult participants in two phase 1 studies: An open-label smoker study and a randomized, placebo-controlled ethnobridging study.
Hayakawa Y, Rospo C, Bartmann AP, et al. · Epilepsia 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from UCB.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.